伏立康唑临床应用安全性研究:基于北京市近10年药品不良反应监测数据  

Safety study of voriconazole clinical application: datas based on 10-year spontaneous reports in Beijing

作　　者：任晓蕾[1] 张晓[2] 詹轶秋[1] 张春燕[1] 黄琳[1] 封宇飞 REN Xiao-lei;ZHANG Xiao;ZHAN Yi-qiu;ZHANG Chun-yan;HUANG Lin;FENG Yu-fei(De-partment of Pharmacy,People’s Hospital,Peking University,Beijing 100044,China;Beijing Center for ADR Monitoring,Bei-jing 100024,China)

机构地区：[1]北京大学人民医院药剂科,北京100044 [2]北京市药品不良反应监测中心,北京100024

出　　处：《中国医院药学杂志》2022年第4期439-442,共4页Chinese Journal of Hospital Pharmacy

摘　　要：目的:以北京地区伏立康唑不良反应(ADR)报告为依据,探讨伏立康唑不良反应的发生特点,为临床用药安全提供依据。方法:对2011年1月1日至2021年6月30日北京市药品不良反应监测中心收集的医疗机构报告中515例伏立康唑相关ADR进行回顾性分析。结果:515例ADR报告中男性293例,女性220例,性别不详2例。静脉滴注给药279例,口服给药220例,静脉滴注序贯口服给药10例,泵内注射4例,鼻饲2例。2例存在超量用药情况。报告中严重ADR 23例(4.47%)。伏立康唑ADR临床表现前3位主要为幻觉、肝功能损害及视觉损害,存在药物相互作用问题。结论:临床应关注伏立康唑的ADR,建议在治疗药物监测引导下实施个体化给药,促进临床安全合理用药。OBJECTIVE Based on the adverse reaction(ADR)report of voriconazole in Beijing, this paper discusses the characteristics of ADR of voriconazole, so as to provide basis for clinical drug safety.METHODS A retrospective analysis of 515 voriconazole-related ADR reports received by Beijing Adverse Drug Reaction Monitoring Center from medical institutions, from January 1 st, 2011 to June 30 th, 2021 was conducted.RESULTS Among 515 ADR reports, there were 293 males, 220 females and 2 unknown genders.Of the deliveries for voriconazole that reported, intravenous infusion, oral, intravenous infusion sequential oral, intra-pump injection and nasal feeding accounted for 279,220,10,4 and 2,respectively.2 overdose cases were found.Severe ADR 23 cases(4.47%)were reported.The most common ADRs for all reports were hallucination, abnormal liver function and visual impairment.Drug-drug interactions were identified in these.CONCLUSION Clinical attention should be paid to ADR of voriconazole.It is suggested to implement individualized administration under the guidance of therapeutic drug monitoring to promote clinical safe and rational drug use.

关 键 词：伏立康唑 不良反应 安全用药 个体化给药 

分 类 号：R978.5[医药卫生—药品]